| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/15/2004 | US20040138109 Viricides such as ciluprevir in solutions of polyethylene glycol, ethanol, propylene glycol, water and/or mixtures, used for prophylaxis or prevention of hepatitis C virus (HCV) infections |
| 07/15/2004 | US20040138105 Modulators of polysaccharides and uses thereof |
| 07/15/2004 | US20040138103 Compositions containing peptide copper complexes and metalloproteinase inhibitors and methods related thereto |
| 07/15/2004 | US20040138101 Prophylaxis of bone disorders comprising administering insulin and derivatives, and optionally in combination with peptide growth factors, metabolic antagonist, osteoprotegerins, synovial or antiinflammatory agents, in sustained release form |
| 07/15/2004 | US20040138074 Warming and nonirritating lubricant compositions and method of comparing irritation |
| 07/15/2004 | US20040137622 Modular transfection systems |
| 07/15/2004 | US20040137620 Compositions corresponding to a calcium transporter and methods of making and using same |
| 07/15/2004 | US20040137573 for drug screening treatments for pain, neuropathy, rheumatoid/osteo arthritis, stroke, inflammation, asthma, allergy, urogenital disorders, incontinence, hypertension, hypotension, perivasular disease; animal models; kits |
| 07/15/2004 | US20040137514 Use of antibodies against specific mhc-peptide complexes |
| 07/15/2004 | US20040137503 for analysing allelic variation a gene, and using polymorphism in treatment of diseases with gene-specific drugs |
| 07/15/2004 | US20040137492 Novel polypeptide |
| 07/15/2004 | US20040137090 Mixture of methylhydroxychalcone polymer (MHCP) and chromium; antidiabetic agents |
| 07/15/2004 | US20040137081 Attaining sexual wellness and health of the sexual vascular system with proanthocyanidins |
| 07/15/2004 | US20040137080 Multivitamin regimen for renal patients |
| 07/15/2004 | US20040137079 A stable aqueous solution of hyaluronic acid, a stabilized oxy-chloro complex, e.g., chlorine dioxide, a boric acid/borate buffer to maintain a pH of 6-9 and no more than 0.0075% hydrogen peroxide; storage; conditioning; increased comfort; dry eye |
| 07/15/2004 | US20040137072 Reducing the risk of osteoporosis and other bone-loss disorders in females; increases the bioavailability of metabolites involved in bone mineral loss and calcium absorption control |
| 07/15/2004 | US20040137068 A sterile formulation of a biocompatible chelating agent, a permeability promoter, Advanced Glycation Endproducts (AGE) selected from breakers, formation inhibitors, and glycation inhibitors and a carrier; vision defects; inserts |
| 07/15/2004 | US20040137066 treating vascular disease by diagnosing the pathology and then coating the implant with the appropriate therapeutic agent to treat it; coating contaings a mixture of rapamycin and another therapeutic agent |
| 07/15/2004 | US20040137054 separated by a physiologically acceptable inert material such as microcrystalline cellulose and/or pregelatinised starch; storage stability; combination dosage for better patient compliance |
| 07/15/2004 | US20040137034 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| 07/15/2004 | US20040137029 modifying a mineral supplement or animal feed through the addition of effective amounts of garlic and sulfur as insect repellant |
| 07/15/2004 | US20040137014 Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
| 07/15/2004 | US20040137001 Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse |
| 07/15/2004 | US20040136997 Identification and development of specific monoclonal antibodies to squamous cell carcinoma |
| 07/15/2004 | US20040136993 inducing an immunogenic response against alpha-SN |
| 07/15/2004 | US20040136983 as anti-tumor agent or treating excessive vascular permeability; agonist for treating trauma to vascular network |
| 07/15/2004 | US20040136979 block, retard or reduce connective tissues regeneration; molecules released by catheters, surgical instruments or stents for angioplasty to prevent restenosis; atherosclerosis |
| 07/15/2004 | US20040136972 Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues |
| 07/15/2004 | US20040136971 Implantation of encapsulated biological materials for treating diseases |
| 07/15/2004 | US20040136970 negatively charged carrier, such as hyaluronic acid, are administered to a synovial joint, the stimulatory effects of the FGF18 are enhanced |
| 07/15/2004 | US20040136954 Methods and compositions for modulating T helper (Th) cell development and function |
| 07/15/2004 | US20040136953 diagnosing aggressive form of respiratory condition by a different T helper cell response when samples are incubated with antigen characteristic of condition; treatment with interferon gamma |
| 07/15/2004 | US20040136949 Combination therapy using anti-angiogenic agents and tnf alpha |
| 07/15/2004 | US20040136922 film delivers at least one oral care agent, such as antimicrobial agents and salivary stimulants |
| 07/15/2004 | US20040136920 aerosol formulation which comprises particulate salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation is substantially free of surfactant |
| 07/15/2004 | US20040136918 salmeterol xinafoate and fluticasone propionate in a metered does inhaler with propellant |
| 07/15/2004 | US20040136904 Dry powder compositions comprising labelled particles for inhalation |
| 07/15/2004 | DE202004006157U1 Pharmaceutical or dietetic product useful for treating headache and migraine comprises a blueberry extract together with vitamins and minerals |
| 07/15/2004 | DE10320604A1 Partikel umfassend ein Biopolymer, das unter Einwirkung von elektromagnetischen Wellen, ausgestrahlt durch Sonneneinstrahlung, abbaubar ist Particles comprising a biopolymer that is under the influence of electromagnetic waves emitted by the sun, degradable |
| 07/15/2004 | DE10300222A1 Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen The use of active substances for the prophylaxis and / or therapy of viral diseases |
| 07/15/2004 | DE10147991B4 Verfahren zur Diagnose von chronisch entzündlichen Darmerkrankungen A method of diagnosing inflammatory bowel disease |
| 07/15/2004 | CA2511606A1 Therapeutic formulations for the treatment of beta-amyloid related diseases |
| 07/15/2004 | CA2511599A1 Therapeutic formulations for the treatment of beta-amyloid related diseases |
| 07/15/2004 | CA2511217A1 Ophthalmic formulation for the prevention and treatment of ocular conditions |
| 07/15/2004 | CA2510315A1 Antibodies against gpr64 and uses thereof |
| 07/15/2004 | CA2510296A1 Steroid compositions for intraocular use |
| 07/15/2004 | CA2510289A1 Pharmaceutical compositions and method of treating parkinson's disease |
| 07/15/2004 | CA2509835A1 Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof |
| 07/15/2004 | CA2509510A1 Method of using a cox-2 inhibitor and a topoisomerase ii inhibitor as a combination therapy in the treatment of neoplasia |
| 07/14/2004 | EP1437595A1 Orphan GPCR gene 115 for obesity indication |
| 07/14/2004 | EP1437592A1 Novel screening method using prokineticin receptor |
| 07/14/2004 | EP1437364A2 Polypeptide binding to the androgen receptor and its potential use for treating breast cancer |
| 07/14/2004 | EP1437139A2 Method for protection against genotoxic mutagenesis |
| 07/14/2004 | EP1437138A1 Use of 7-oxo DHEA in the modulation of the metabolism of a dieting mammal |
| 07/14/2004 | EP1437137A1 Drugs comprising combination of antithrombotic agent with pyrazolone derivative |
| 07/14/2004 | EP1437131A1 Use of an ACE inhibitor for the prevention of diabetes in a patient with no preexisting congestive heart failure |
| 07/14/2004 | EP1437052A1 Ocuvite Zinc |
| 07/14/2004 | EP1437043A1 Model animal with overexpression of regucalcin |
| 07/14/2004 | EP1436624A1 A method of diagnosis and treatment and agents useful for same |
| 07/14/2004 | EP1436623A1 Modulation of tor |
| 07/14/2004 | EP1436429A2 Targeted nucleic acid constructs and uses related thereto |
| 07/14/2004 | EP1436395A2 Methods for identifying and using modulators of estrogen related receptor gamma |
| 07/14/2004 | EP1436383A2 Secreted proteins |
| 07/14/2004 | EP1436382A2 9136, a human aldehyde dehydrogenase family member and uses therefor |
| 07/14/2004 | EP1436380A2 Composition comprising a lactobacillus pentosus strain and uses thereof |
| 07/14/2004 | EP1436329A1 Anti-pdgf antibodies and methods for producing engineered antibodies |
| 07/14/2004 | EP1436327A1 Ee3-protein family and corresponding dna sequences |
| 07/14/2004 | EP1436323A1 Crystal structure of baff, and use thereof in drug design |
| 07/14/2004 | EP1436316A2 Subcellular targeting of therapeutic proteins |
| 07/14/2004 | EP1436291A2 Indolizines as kinase protein inhibitors |
| 07/14/2004 | EP1436290A1 Alkyne-aryl-naphthyridin-4(1h)-0ne derivatives as type iv phosphodiesterase inhibitor |
| 07/14/2004 | EP1436281A1 Piperidine- and piperazineacetamides as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 07/14/2004 | EP1436257A1 Low-calcemic oxime analogs of 1alpha, 25-dihydroxy vitamin d3 |
| 07/14/2004 | EP1436029A2 Methods and apparatuses for assuring quality and safety of drug administration and medical products and kits |
| 07/14/2004 | EP1436013A2 Method for inducing growth and enhancing survival of nervous tissue |
| 07/14/2004 | EP1436012A2 Polymer conjugates of opioid antagonists |
| 07/14/2004 | EP1436008A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound |
| 07/14/2004 | EP1436000A2 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
| 07/14/2004 | EP1435992A2 Chemokines as adjuvants of immune response |
| 07/14/2004 | EP1435988A1 Improved use of antitumoral compound in cancer therapy |
| 07/14/2004 | EP1435987A1 Method and composition for treating immune complex associated disorders |
| 07/14/2004 | EP1435986A2 Igf-binding protein-derived peptide or small molecule |
| 07/14/2004 | EP1435985A2 Medicament containing activated antithrombin iii |
| 07/14/2004 | EP1435984A1 Use of histamine to treat liver disease |
| 07/14/2004 | EP1435974A2 Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
| 07/14/2004 | EP1435973A1 Coadministration of transport protein with conjugated cobalamin to deliver agents |
| 07/14/2004 | EP1435971A1 Utilization of phosphatidylserine in the treatment of attention deficit syndrome (adhs) |
| 07/14/2004 | EP1435970A2 Methods of treating skin with diphosphonate derivatives |
| 07/14/2004 | EP1435968A1 Combinations comprising cox-2 inhibitors and aspirin |
| 07/14/2004 | EP1435967A2 Methods for preventing and treating bone loss with steroid compounds |
| 07/14/2004 | EP1435965A2 Pharmaceutical compositions and methods for treating cancer |
| 07/14/2004 | EP1435963A2 Reduced toxicity cisplatin formulations and methods for using the same |
| 07/14/2004 | EP1435960A1 Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine a2a receptor antagonists |
| 07/14/2004 | EP1435959A2 Inhibitors of the egf receptor for the treatment of thyroid cancer |
| 07/14/2004 | EP1435956A2 Therapeutic combinations for cardiovascular and inflammatory indications |
| 07/14/2004 | EP1435948A1 Aminoisoxazole derivatives active as kinase inhibitors |
| 07/14/2004 | EP1435947A1 2-phenyl benzimidazoles and imidazo-[4,5]-pyridines as cds1/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer |
| 07/14/2004 | EP1435938A1 Modulation of ocular growth and myopia by gaba drugs |
| 07/14/2004 | EP1435935A2 Concentrated x-ray contrast media can act as universal antigens and can inhibit or prevent allergic reactions |
| 07/14/2004 | EP1435927A2 Method for treating skin disorders |